KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation and Depletion: 2020-2024

Historic Depreciation and Depletion for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $6.2 million.

  • Recursion Pharmaceuticals' Depreciation and Depletion rose 47.62% to $6.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.3 million, marking a year-over-year increase of 14.38%. This contributed to the annual value of $18.3 million for FY2024, which is 15.09% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $6.2 million for Q4 2024, which was up 55.00% from $4.0 million recorded in Q3 2024.
  • Recursion Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $6.2 million during Q4 2024, with a 5-year trough of $1.0 million in Q1 2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median Depreciation and Depletion value was $4.0 million (recorded in 2024), while the average stood at $3.8 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Depreciation and Depletion soared by 140.00% in 2021, and later declined by 4.76% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $1.1 million in 2020, then spiked by 127.27% to $2.5 million in 2021, then climbed by 24.00% to $3.1 million in 2022, then soared by 35.48% to $4.2 million in 2023, then soared by 47.62% to $6.2 million in 2024.
  • Its Depreciation and Depletion was $6.2 million in Q4 2024, compared to $4.0 million in Q3 2024 and $4.1 million in Q2 2024.